RTI Surgical

RTI Surgical is a medical technology company based in Alachua, Florida, whose business grew out of the University of Florida Tissue Bank. The company was established in 1998 when the tissue bank transferred its allograft-processing operations, associated equipment and technologies, distribution arrangements, and research-and-development activities to a newly formed enterprise then known as Regeneration Technologies. The transaction was regarded as a significant University of Florida technology transfer and gave the new company an operating foundation in the processing and distribution of human tissue for medical use. The business developed around tissue-based products and surgical biologics rather than conventional pharmaceutical medicines. Its activities have included the processing, preparation, and commercialization of human-tissue allografts and related products used by medical professionals in surgical settings. The company’s scope expanded through corporate development, including the July 2013 acquisition of Pioneer Surgical by RTI Biologics. Following that transaction, the combined company adopted the name RTI Surgical, reflecting a broader surgical-products identity. RTI Surgical has operated across areas connected with orthopedic, spine, sports-medicine, and other surgical applications, although the available reference material does not provide a complete current product catalog or market-by-market breakdown. Its business has included both branded medical products and original-equipment-manufacturer activities. In 2020, Montagu Private Equity acquired RTI Surgical’s OEM business. The transaction marked a significant portfolio and business-structure change, separating or transferring that OEM activity while RTI Surgical continued as a medical technology company under private ownership. The company has also faced scrutiny concerning the sourcing and consent documentation of human tissue. In 2012, RTI was named as a defendant in civil litigation connected with the body-snatching activities associated with Michael Mastromarino and other tissue suppliers. The allegations concerned whether suppliers had appropriate authority and consent to obtain human tissue and whether organizations receiving tissue had sufficiently investigated the credentials and practices of those suppliers. RTI’s legal position, as reported in the reference material, included an argument that it could accept tissue without civil liability when it lacked actual knowledge of a donor’s contrary intent and that the law did not require it to investigate consent in the manner alleged. The litigation was postponed in September 2012 to facilitate mediation involving settlements for plaintiff families. The case and related allegations are part of the company’s documented history, but the supplied material does not establish a final adjudication of all claims. RTI Surgical’s positioning is therefore built around regulated surgical technology, tissue-based medical products, and supply-chain and processing expertise. Its history combines university-derived biotechnology, acquisitions in surgical products, OEM manufacturing or supply, and private-equity ownership. Detailed information about current executives, revenue, geographic sales, individual product brands, and present corporate structure is not established by the supplied references.

RTI Surgical traces its origins to the University of Florida Tissue Bank in Alachua, Florida. In February 1998, the tissue bank transferred its allograft-processing operations, related equipment and technologies, distribution arrangements, and research-and-development activities to a new company called Regeneration Technologies. This transaction created the operating basis for RTI and represented a major university technology-transfer project. Rather than beginning as a conventional consumer-facing brand, the company emerged from an academic tissue-bank operation and entered the medical technology sector with expertise in the handling and processing of human tissue for clinical use. The company’s core activities centered on tissue allografts and surgical biologics. These products are derived from donated human tissue and processed for use in medical procedures. RTI’s business consequently depended not only on product development and distribution, but also on donor-consent procedures, tissue recovery, processing controls, and regulatory compliance. The available reference material does not provide a full chronology of product launches or regulatory approvals, but it identifies allograft processing and related research as foundational parts of the company’s operations. A significant expansion occurred in July 2013, when RTI Biologics acquired Pioneer Surgical. Following the acquisition, the company was renamed RTI Surgical. The name change reflected the organization’s broader scope across surgical products and its evolution beyond the original Regeneration Technologies identity. The transaction also connected the company’s tissue-based biologics activities with a wider surgical-product portfolio. RTI’s history includes a major legal and reputational controversy concerning tissue sourcing. In 2012, the company was named as a defendant in civil litigation associated with Michael Mastromarino and organizations alleged to have obtained human tissue and body parts through improper means. The allegations included claims that consent documents had been forged and that bodies had been opened and tissue removed without proper authorization. The litigation questioned whether RTI had adequately examined the credentials and conduct of the organizations supplying tissue. RTI’s legal representatives argued that the company could accept tissue without civil liability when it lacked actual knowledge of a donor’s contrary intent and that it was not legally required to investigate consent in the way plaintiffs claimed. In September 2012, proceedings were postponed to enable mediation relating to settlements with affected plaintiff families. The supplied material does not establish a definitive resolution of every allegation or claim. In 2020, Montagu Private Equity acquired RTI Surgical’s OEM business. The transaction changed the structure of the company’s activities by transferring the original-equipment-manufacturer portion of the business to Montagu. It also illustrates the importance of OEM operations alongside RTI’s branded and tissue-based surgical activities. No current public-company listing, stock ticker, detailed ownership structure, or current executive roster is established in the supplied sources. RTI Surgical is therefore best characterized on the available evidence as an active, privately owned medical technology company with origins in a university tissue bank and a business history spanning allografts, surgical products, acquisitions, litigation over tissue sourcing, and OEM divestiture or transfer.

• 2020

  Montagu Private Equity acquires the OEM business

  [1]RTI Surgicalen.wikipedia.org

  Montagu Private Equity acquired RTI Surgical’s original-equipment-manufacturer business.

• 2013

  Pioneer Surgical is acquired and the company adopts the RTI Surgical name

  [1]RTI Surgicalen.wikipedia.org

  RTI Biologics acquired Pioneer Surgical in July 2013 and subsequently renamed the combined organization RTI Surgical.

• 2012

  Civil litigation over tissue sourcing

  [1]RTI Surgicalen.wikipedia.org

  RTI became a defendant in litigation concerning tissue suppliers linked to Michael Mastromarino and allegations involving improper body-part procurement and consent documentation.

• 1998

  Regeneration Technologies is established through a University of Florida spin-off

  [1]RTI Surgicalen.wikipedia.org

  The University of Florida Tissue Bank transferred its allograft-processing operations, equipment, technologies, distribution arrangements, and research activities to Regeneration Technologies in February 1998.

A specialized medical technology and surgical biologics company focused on human-tissue allografts, tissue processing, and related products for surgical applications.

• Surgical biologics

  Human-tissue allografts

  Human-tissue allografts are donated-tissue products processed for use in surgical and reconstructive procedures. They are central to RTI Surgical’s historical identity because the company originated from the University of Florida Tissue Bank’s allograft-processing operations. The supplied references do not identify individual product names, indications, or current availability.

• Surgical products

  Orthopedic and spine surgical products

  RTI Surgical’s post-2013 identity encompassed a broader surgical-products portfolio following the acquisition of Pioneer Surgical. The available material supports an association with orthopedic and spine-related surgical applications, but does not provide a sufficiently detailed current catalog or individual product specifications.

• Medical-device manufacturing

  OEM medical products

  OEM activities formed a distinct part of RTI Surgical’s business and were acquired by Montagu Private Equity in 2020. The supplied sources do not specify the individual devices, components, customers, or manufacturing sites included in the transaction.

• 2012

  Litigation concerning tissue suppliers and donor consent

  RTI was named in civil litigation connected to organizations associated with Michael Mastromarino. Plaintiffs alleged that human tissue had been obtained improperly, including through forged consent documents, and questioned whether RTI had sufficiently investigated its suppliers. RTI disputed the asserted legal basis for liability. The proceedings were postponed in September 2012 for mediation involving plaintiff families.

  Source

Read more

• 2020

  Transfer the OEM business to Montagu Private EquityM&A

  Background

  RTI Surgical’s original-equipment-manufacturer operations became the subject of a private-equity transaction.

  Action taken

  Montagu Private Equity acquired RTI Surgical’s OEM business.

  Aftermath

  The transaction changed the composition and ownership of the company’s OEM activities; the supplied sources do not describe the subsequent operating structure in detail.

  Source

• 2013

  Acquire Pioneer Surgical and rename the combined companyM&A

  Background

  RTI Biologics pursued an expansion of its surgical-products business through the acquisition of Pioneer Surgical.

  Action taken

  Pioneer Surgical was acquired in July 2013, after which the company adopted the RTI Surgical name.

  Aftermath

  The transaction broadened the organization’s identity from a biologics-focused business to a wider surgical-products company.

  Source

• 2020

  Montagu Private Equity acquires RTI Surgical’s OEM business[1]RTI Surgicalen.wikipedia.org

  M&A

  Montagu Private Equity acquired RTI Surgical’s OEM business, representing a major ownership and portfolio transaction involving the company’s original-equipment-manufacturer operations.

• 2013

  RTI Biologics acquires Pioneer Surgical[1]RTI Surgicalen.wikipedia.org

  M&A · Leadership change

  RTI Biologics acquired Pioneer Surgical in July 2013. The combined company subsequently changed its name to RTI Surgical.

1. 1RTI Surgicalen.wikipedia.org